QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

20,995 signal articles · 492 in last 24h · 103,318 total before filter · latest 1h ago
492last 24h
2476last 7d
479● bullish (7d)
251● bearish (7d)
197publishers
AllMacro242Earnings1457M&A138Regulatory16Product4Analyst29
✕ clear all filtersticker: LCIDSentiment:bullishneutralbearishshow all (incl. clickbait)
Lucid Group Q2 Earnings Call Highlights
MarketBeat15h agoneutral
Lucid Group Q2 Earnings Call Highlights

Lucid Group (NASDAQ:LCID) outlined a broad operational reset during its second-quarter 2026 earnings call, with newly appointed CEO Silvio Napoli saying the electric-vehicle maker is targeting approximately $1.4 billion in cash-flow improvements this year while reducing production, lowering inventor

Citi Cuts Lucid Price Target to $14: Q1 Miss, Pulled Guidance Test the Saudi-Backed EV Maker
24/7 Wall St.81d agobearish
Citi Cuts Lucid Price Target to $14: Q1 Miss, Pulled Guidance Test the Saudi-Backed EV Maker

Citi just trimmed its price target on Lucid Group (NASDAQ:LCID) to $14 from $17, while keeping a Buy rating. Analyst Michael Ward cited the company’s Q1 2026 miss and the withdrawal of its 2026 outlook, but argued the medium-term thesis remains intact. For long-term investors, the price target cut reads as a sobering near-term recalibration ... Citi Cuts Lucid Price Target to $14: Q1 Miss, Pulled Guidance Test the Saudi-Backed EV Maker

Lucid Diagnostics Q1 Earnings Call Highlights
MarketBeat82d agoneutral
Lucid Diagnostics Q1 Earnings Call Highlights

Lucid Diagnostics (NASDAQ:LUCD) reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination and is expanding efforts with the Department of Veterans Affairs, commercial payers and health sys